Radiation Therapy Department Reorganization during the Coronavirus Disease 2019 (COVID-19) Outbreak: Keys to Securing Staff and Patients During the First Weeks of the Crisis and Impact on Radiation Therapy Practice from a Single Institution Experience.


Journal

Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247

Informations de publication

Date de publication:
Historique:
received: 21 04 2020
revised: 24 04 2020
accepted: 27 04 2020
entrez: 11 8 2020
pubmed: 11 8 2020
medline: 11 8 2020
Statut: epublish

Résumé

During the first weeks of the coronavirus disease 2019 (COVID-19) outbreak in France, it was necessary to clearly define organizational priorities in the radiation therapy (RT) departments. In this report, we focus on the urgent measures taken to reduce risk for both our staff and patients by reducing the number of patients receiving treatment. We reviewed the fractionation schemes for all patients in our department, including those receiving treatment and those soon to start treatment. Our goals were to (1) decrease the number of patients coming daily to the hospital for RT, (2) adapt our human resources to continue patients' care in the department, and (3) help to cover understaffed COVID-19 sectors of the hospital. We identified 50 patients who were receiving treatment (n = 6), were going to start radiation after CT scan simulation (n = 41), or for whom the CT scan was pending (n = 3). The majority were women (64%) treated for breast cancer (54%). RT was delayed for 22 (44%) patients. The majority were offered hormone therapy as "waiting therapy." Hypofractionation was considered in 21 (42%) patients mainly with breast cancer (18 of 21, 86%). The number of courses initially planned and replanned as a result of the COVID-19 outbreak during the period of March 15 to May 31, 2020, were 1383 and 683, respectively, which represented a reduction of 50% (including delayed sessions) that allowed our reorganization process. To conserve resources during the pandemic, we successfully reduced the number of patients receiving treatment in a proactive fashion and adapted our organization to minimize the risk of COVID-19 contamination. Departments across the world may benefit from this same approach.

Identifiants

pubmed: 32775775
doi: 10.1016/j.adro.2020.04.039
pii: S2452-1094(20)30142-1
pmc: PMC7250781
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

644-650

Informations de copyright

© 2020 The Authors.

Références

Clin Oncol (R Coll Radiol). 2020 May;32(5):279-281
pubmed: 32241520
Adv Radiat Oncol. 2020 Apr 01;5(4):659-665
pubmed: 32292839
Asian Pac J Cancer Prev. 2020 Mar 01;21(3):569-573
pubmed: 32212779
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
J Clin Oncol. 2017 Jun 20;35(18):2037-2043
pubmed: 28459606
mSystems. 2020 Apr 7;5(2):
pubmed: 32265315
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
Clin Transl Radiat Oncol. 2020 Mar 24;22:55-68
pubmed: 32274425
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1788-1795
pubmed: 32279081
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):563-570
pubmed: 28126305
J Clin Oncol. 2013 Jul 1;31(19):2382-7
pubmed: 23690420
Bull Cancer. 2020 May;107(5):528-537
pubmed: 32278467
J Clin Oncol. 2015 Feb 1;33(4):332-9
pubmed: 25534388
Radiother Oncol. 2020 Jun;147:100-102
pubmed: 32259751
Cancer Radiother. 2020 Apr;24(2):87
pubmed: 32299663
Cancer Radiother. 2020 Jun;24(3):182-187
pubmed: 32307313
Lancet Oncol. 2015 Jan;16(1):47-56
pubmed: 25500422

Auteurs

Yazid Belkacemi (Y)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.
Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM), U955 Team 21, and University Paris-Est Creteil (UPEC), Paris, France.
Association of Radiotherapy and Oncology of the Mediterranean Area (AROME), Paris, France.
TransAtlantic Radiation Oncology Network (TRONE), Paris, France.

Gokoulakrichenane Loaganadane (G)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.
Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM), U955 Team 21, and University Paris-Est Creteil (UPEC), Paris, France.
TransAtlantic Radiation Oncology Network (TRONE), Paris, France.

Noémie Grellier (N)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.
Association of Radiotherapy and Oncology of the Mediterranean Area (AROME), Paris, France.

Gloria Fonteneau (G)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.

Gaël Zaoui (G)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.

Gabriele Coraggio (G)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.
Association of Radiotherapy and Oncology of the Mediterranean Area (AROME), Paris, France.

Asma Hadhri (A)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.
Association of Radiotherapy and Oncology of the Mediterranean Area (AROME), Paris, France.

Marie Adou (M)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.

Jerôme Bendavid (J)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.

Angela Boros (A)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.

Sahar Ghith (S)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.
Association of Radiotherapy and Oncology of the Mediterranean Area (AROME), Paris, France.

Kamel Debbi (K)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.
Association of Radiotherapy and Oncology of the Mediterranean Area (AROME), Paris, France.

Pauline Cadot (P)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.

Adeline Bak (A)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.

Cindy Le Bret (C)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.

Wissal Hassani (W)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.
Association of Radiotherapy and Oncology of the Mediterranean Area (AROME), Paris, France.

Mathilde Mahé (M)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.

Marie-Laure Hervé (ML)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.

Laurianne Colson-Durand (L)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.

Nhu Hanh To (N)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.
Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM), U955 Team 21, and University Paris-Est Creteil (UPEC), Paris, France.
TransAtlantic Radiation Oncology Network (TRONE), Paris, France.

Deng Feng Luo (DF)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.
TransAtlantic Radiation Oncology Network (TRONE), Paris, France.

Aziz Cherif (A)

Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.
Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM), U955 Team 21, and University Paris-Est Creteil (UPEC), Paris, France.
Association of Radiotherapy and Oncology of the Mediterranean Area (AROME), Paris, France.

Classifications MeSH